Phase 3 Open-Label Study Evaluating the Efficacy and Safety of Mavacamten in Japanese Adults With Obstructive Hypertrophic Cardiomyopathy　― The HORIZON-HCM Study

Background: Mavacamten, a cardiac myosin inhibitor, significantly improved symptoms and cardiac function vs. placebo in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in EXPLORER-HCM. However, the efficacy and safety profiles of mavacamten in Japanese patients are unclear.Me...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Circulation Journal 2024/11/07, pp.CJ-24-0501
Hauptverfasser:	Kitaoka, Hiroaki, Ieda, Masaki, Ebato, Mio, Kozuma, Ken, Takayama, Morimasa, Tanno, Kaoru, Komiyama, Nobuyuki, Sakata, Yasushi, Maekawa, Yuichiro, Minami, Yuichiro, Ogimoto, Akiyoshi, Takaya, Tomofumi, Yasuda, Satoshi, Amiya, Eisuke, Furukawa, Yutaka, Watanabe, Tetsuya, Hiraya, Daigo, Miyagoshi, Hidetaka, Kinoshita, Gen, Reedy, Alison, Hegde, Sheila M., Florea, Victoria, Izumi, Chisato
Format:	Artikel
Sprache:	eng
Schlagworte:	Efficacy Hypertrophic cardiomyopathy Mavacamten Safety
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!